COVID-19 @ NIBIB

Share:

EmailFacebookLinkedInXWhatsAppShare

Covid-19 Banner

NIBIB's goal is to accelerate research, translation, and commercialization of technologies that will provide solutions to the COVID-19 pandemic.

NIBIB is administering the RADx® Tech and Advanced Technology Platforms (ATP) programs. These programs are part of the NIH RADx® Initiative to increase testing capacity and accessibility for SARS-CoV-2, the virus that causes COVID. In addition, NIBIB is supporting other technology development, imaging approaches, and digital platforms to address the pandemic.

Rapid Acceleration of Diagnostics (RADx®) Tech and ATP Programs

The RADx® Tech program is part of the NIH RADx® Initiative to increase testing capacity and accessibility for SARS-CoV-2, the virus that causes COVID. 

Summary data on proposals submitted to the RADx® Tech and ATP Programs.

The MakeMyTestCount.org website is an easy way to anonymously report test results for any brand of at-home COVID-19 test. This helps public health departments to assess needs and provide resources. Report your test results here

COVID-19 Research across NIBIB

Listing of COVID-19 related grants funded by NIBIB.

Learn how this collaborative network is using medical imaging and clinical data sciences to reveal unique features of COVID-19. Learn more about this resource.

Videos

View videos about RADx® Tech/ATP programs, interviews with the NIBIB Director and more.

Program Contacts

RADx® Tech/ATP programmatic or technical inquiries: info.radx@poctrn.org

All other RADx® Tech/ATP Applicants: RADxNIBIB@mail.nih.gov

SBIR/STTR Applicants: NIBIB-SBIR@mail.nih.gov

All others: COVID19NIBIB@nih.gov

Related News

October 31, 2024

NIH has announced winners of the RADx® Tech Fetal Monitoring Challenge, a $2 million prize competition to speed development of innovative medical technologies for fetal health diagnosis, detection and monitoring.

October 28, 2024

A team of engineers at the University of Houston has published a study in the journal Nature on how international air travel has influenced the spread of COVID-19 around the world. By using a newly developed AI tool, the team identified hotspots of infection linked to air traffic, pinpointing key areas that significantly contribute to disease transmission. Source: University of Houston Newsroom

October 21, 2024
A headshot of Kaitlyn Sadtler at the TIME100 Next Gala 2024. Credit: Leonardo Munoz/AFP via Getty Images

NIBIB bioengineer Kaitlyn Sadtler has flourished as a leader of many impactful, interdisciplinary studies. For her role in shaping the future of medical research, TIME magazine has named Kaitlyn Sadtler to the TIME100 Next 2024 List.

October 17, 2024

NIBIB-funded researchers are working to bring in vivo gene editing to the fore. Through rational engineering of lipid nanoparticles, this collaborative team developed a way to effectively target specific organs in the body to precisely deliver therapeutic cargo, including gene-editing molecules. Their research demonstrated that a one-time treatment with their nanoparticles resulted in durable gene editing in mouse lungs for nearly two years. Further, their technique showed promise in correcting a mutation present in a currently untreatable form of cystic fibrosis in several models of the disease.

July 22, 2024
A photograph of the LIAMT handheld processor

Due to its high accuracy, lab-based PCR testing is the gold standard for infectious disease diagnostics. Yet PCR's availability is limited, especially in low-resource settings. New research suggests a new kind of test could be more streamlined without sacrificing performance.